中文
[an error occurred while processing this directive]
Zhiyuan Zhong, Professor
Ph.D. Supervisor
Phone number:0512-65880098
e-mail: zyzhong@suda.edu.cn
Mailing address: Room 0710, Building 912, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, 199 Ren'ai Road, Suzhou Industrial Park. Postcode 215123
Professor Zhiyuan Zhong is a distinguished professor and chair of Soochow University Biomedical Polymers Laboratory, and director of Targeted Radiopharmaceuticals Innovation and Translation Center, State Key Laboratory of Radiation Medicine and Protection. He received his Ph.D. in 2002 from the University of Twente (The Netherlands) under the supervision of Prof. Dr. Jan Feijen. In 2011-2012, he worked as a Vice President of Suzhou BioBay (a top Biomedical Park in China). His research focuses on biomedical polymers, nanomedicines and targeted cancer therapy. He has co-authored ca. 250 papers with more than 18000 times of citation and an H-Index of 72 (web of science). He has been listed as aHighly Cited Researcherin 2018 and 2019(Clarivate Analytics). He has filed over 50 patents, among which 11 has been licensed to a pharmaceutical company. He has co-founded a biomedical company, AK Cell Biopharma Co., Ltd., focusing on clinical translation of targeted formulations. He is an Asian Associate Editor for J. Controlled Release, has served as an Associate Editor for Biomacromolecules (ACS) from 2015 to 2019, an Editorial/Advisory Board Member for 10 journals including Mater. Today, J. Controlled Release, Nanotechnology, Nano Futures, PLoS One, Acta Pharmaceutica Sinica B,J. Gene Med., and J. Biomater. Sci. Polym. Ed., and an Executive Chair for the 1st-6th Symposium on Innovative Polymers for Controlled Delivery (SIPCD 2010, 2012, 2014, 2016, 2018 and 2020) held biennially in Suzhou, China. He has received several awards including Biomacromolecules/Macromolecules Young Investigator Award (ACS), the Friedrich Wilhelm Bessel Research Award (Humboldt Foundation), Award for Breakthrough Technologies in Drug Delivery Systems in Asia (Japanese Society of Drug Delivery System), National Ten-Thousand Talent Award, and National Outstanding Young Scholar Award. In 2018, he has been elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).
Main research directions:
Biomedical polymers, nanomedicines and targeted cancer therapy
Representative articles:
1、Y.H. Wei, F.H. Meng*, G. Storm, and Z.Y. Zhong*, Transferrin-Binding Peptide Functionalized Polymersomes Mediate Targeted Doxorubicin Delivery to Colorectal Cancer In Vivo, J. Control. Release 2020, 319, 407-415.
2、Y.N. Zhong, F.H. Meng*, W. Zhang, B. Li, J. van Hest, andZ.Y. Zhong*, CD44-Targeted Vesicles Encapsulating Granzyme B as Artificial Killer Cells for Potent Inhibition of Human Multiple Myeloma in Mice, J. Control. Release 2020, 320, 421-430.
3、X.L. Gu, Z.H. Zhu, Y.H. Wei, G.L. Wang, F.H. Meng, Z.Y. Zhong*, and C. Deng*, Nano-Agents Based on Poly(ethylene glycol)-b-Poly(L-thyroxine) Block Copolypeptide for Enhanced Dual-Modality Imaging and Targeted Tumor Radiotherapy,Small 2019, 15, 1902577.
4、W.X. Gu, J.N. An, H. Meng, N. Yu, Y.N. Zhong, F.H. Meng*, Y. Xu*, J.L.M. Cornelissen, andZ.Y. Zhong*, CD44-Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma, Adv. Mater. 2019, 1904742.
5、X.L. Gu, Y.H. Wei, Q.Y. Fan, H.L. Sun, R. Cheng, Z.Y. Zhong*, and C. Deng*, cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo, J. Control. Release 2019, 301, 110-118.
6、N. Rades, K. Achazi, M. Qiu, C. Deng, R. Haag, Z.Y. Zhong*, and K. Licha*, Reductively cleavable polymer-drug conjugates based on dendritic polyglycerol sulfate and monomethyl auristatin E as anticancer drugs, J. Control. Release 2019, 300, 13-21.
7、X. Xu, W.J. Yang, Y.N. Shi, W.X. Zhang, X. Wang, F.H. Meng, and Z.Y. Zhong*, and L.C. Yin*, Efficient and Targeted Drug/siRNA Co-Delivery Mediated by Reversibly Crosslinked Polymersomes toward Anti-Inflammatory Treatment of Ulcerative Colitis (UC),Nano Res. 2019, 12, 659-667.